ABSTRACT:
Gastroretentive Drug Delivery Systems (GRDDS) are advanced pharmaceutical formulations designed to extend the residence time of a drug in the stomach, enhancing its therapeutic efficacy and bioavailability. This system is particularly beneficial for drugs that are poorly absorbed in the lower gastrointestinal tract or require prolonged gastric retention for optimal effectiveness. GRDDS address the challenges associated with conventional drug delivery methods by employing various mechanisms such as buoyancy, swelling, and bioadhesion to prolong gastric retention. Key advantages include improved bioavailability for drugs with a narrow absorption window, enhanced patient compliance due to reduced dosing frequency, and targeted local action for conditions such as peptic ulcers. GRDDS candidates typically include drugs with localized action in the stomach, those absorbed primarily in the stomach, or those poorly soluble in alkaline pH. Various GRDDS approaches, such as floating systems, mucoadhesive systems, and high-density systems, offer diverse strategies to achieve prolonged gastric residence. The current market includes GRDDS products for managing peptic ulcers and gastroesophageal reflux disease, leveraging innovative materials and technologies such as hydrogels and magnetic systems. Future perspectives of GRDDS are promising, with ongoing research focused on enhancing drug bioavailability, reducing side effects, and improving patient compliance. Continued development in this field aims to optimize drug delivery, provide targeted treatments, and address the limitations of traditional dosage forms, ultimately revolutionizing pharmaceutical care and therapeutic outcomes.
Cite this article:
Mohammad Zaid, Prof. Imran Kalam, Dr. Quazi Majaz. Gastro Retentive Drug Delivery System. IJRPAS, Sept – Oct 2024; 3(5): 6-16.